News from Ryvu Therapeutics S.A.

Reset filter

Reset filter

Saved filters

To save filters, please log in.

Sorting
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
4.11.2026 16:27

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted available…
Poland
Ryvu Therapeutics S.A.
Unknown author
Industry, Pharmaceutical industry, Healthcare, Healthcare and hospitals
  • Download
nCage and Ryvu Continue to Progress their Collaboration on Next Generation Drug Delivery Systems
nCage and Ryvu Continue to Progress their Collaboration on Next Generation Drug Delivery Systems
28.10.2026 10:45

nCage and Ryvu Continue to Progress their Collaboration on Next Generation Drug Delivery Systems

Ryvu Therapeutics and nCage report encouraging early in vitro results from their collaboration to develop targeted drug delivery systems based on nCage’s TRAP cage platform. The partners plan to continue exploring its potential for oncology.
Poland
Ryvu Therapeutics S.A.
Unknown author
Economy, Companies, Industry, Pharmaceutical industry, Science, Science and research
  • Download
Sorting